A quick update on Apoptone in hormone-refractory prostate cancer

Posted on June 12, 2010 by Sitemaster

Back in 2008 we first mentioned the initiation of clinical trials of a drug called Apoptone or HE3235 in men with hormone-refractory prostate cancer. Data on the development of Apoptone was another item on the agenda at the annual meeting of the American Society of Clinical Oncology (ASCO) earlier this week. … READ MORE …

Filed under: Drugs in development, Uncategorized | Tagged: , , , | Leave a comment »

The Tuesday news report: January 27, 2009

Posted on January 27, 2009 by Sitemaster

Today’s news deals with such items as:

  • Toxicities associated with hypofractionated, intensity-modulated radiation therapy
  • Incidental prostate cancer in male patients undergoing radical cystoprostatectomy for treatment of bladder cancer
  • A Spanish review of photodynamic therapy
  • A proposed mechanism of action for the investigational drug Apoptone™ (HE3235) … READ MORE …

Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment, Uncategorized | Tagged: , , , , , | Leave a comment »

The prostate cancer news for Thursday, July 30

Posted on July 31, 2008 by Sitemaster

News items today are focused on information about:

  • a new way of approaching treatment of hormone-refractory disease
  • the initial clinical trials of a new drug candidate in hormone-refractory patients
  • the association between hospital and surgeon volume and patient outcomes after radical prostatectomy. … MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , , , , , , , | Leave a comment »